

# MITOMYCIN Modified de Gramont

## INDICATION (ICD10) C18, C20

1. Advanced colorectal cancer (unlicensed). PS 0, 1, 2

## REGIMEN

### Mitomycin to be given first

Day 1 MITOMYCIN 6mg/m<sup>2</sup> IV bolus  
CALCIUM LEVOFOLINATE 175mg in glucose 5% IV infusion over 30 minutes  
FLUOROURACIL 400mg/m<sup>2</sup> IV bolus  
FLUOROURACIL 2400mg/m<sup>2</sup> continuous IV infusion over 46 hours

Day 15 CALCIUM LEVOFOLINATE 175mg in glucose 5% IV infusion over 30 minutes  
FLUOROURACIL 400mg/m<sup>2</sup> IV bolus  
FLUOROURACIL 2800mg/m<sup>2</sup> continuous IV infusion over 46 hours

NB Calcium levofolinate is not the same as calcium folinate (calcium leucovorin).  
Calcium levofolinate is a single isomer of folinic acid and the dose is generally half that of calcium folinate. If calcium levofolinate is not available calcium folinate (leucovorin) may be used instead.

## CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 28 days for 3 to 6 cycles (review after 3 cycles)

## ANTI-EMETICS

Low emetogenic risk days 1 and 15

## CONCURRENT MEDICATION REQUIRED

|              |  |
|--------------|--|
| Fluorouracil | Mouth and bowel support eg Loperamide, benzydamine mouthwash |
|--------------|--|

## EXTRAVASATION AND TYPE OF LINE / FILTERS

Fluorouracil – inflammitant

Mitomycin - vesicant

Central line (single lumen)

## INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs days 1 and 15 each cycle

Neutrophils x 10<sup>9</sup>/L ≥1.5 give

Platelets x 10<sup>9</sup>/L ≥100 give

Creatinine clearance (GFR) calculated, at the Consultants discretion

Serum creatinine

DPD test

Baseline weight and every cycle

## MAIN TOXICITIES AND ADVERSE REACTIONS

|              |   |
|--------------|---|
| Fluorouracil | Palmar plantar (handfoot syndrome) causing red palms and soles – treat with pyridoxine 50mg tds<br>Diarrhoea – treat with loperamide or codeine<br>Cardiotoxicity – monitor cardiac function. Special attention is advisable in treating patients with a history of heart disease, arrhythmias or angina pectoris or those who develop chest pain during treatment with fluorouracil.<br>Stomatitis |
|--------------|---|

## INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

|              |   |
|--------------|---|
| Fluorouracil | Cimetidine slightly increases exposure to fluorouracil<br>Metronidazole increased toxicity<br>Phenytoin concentration increased<br>Warfarin |
|--------------|---|

## DOSE MODIFICATIONS

Mitomycin maximum lifetime dose = 60mg/m<sup>2</sup>

### Haematological

If neutrophils <1.5x10<sup>9</sup>/L and/or the platelet count <100x10<sup>9</sup>/L delay the course by one week, recheck blood count.

### Hepatic impairment

Fluorouracil

Significantly impaired hepatic function eg bilirubin >50micromol/L may be a sign of disease progression and require cessation of, or change in, treatment. Always discuss deteriorating liver function with consultant.

|                         |                 |
|-------------------------|-----------------|
| Bilirubin >85micromol/L | not recommended |
|-------------------------|-----------------|

### Renal impairment

Fluorouracil

|                |                         |
|----------------|-------------------------|
| CrCl >30ml/min | give 100% dose          |
| CrCl <30ml/min | consider dose reduction |

Mitomycin

|                |                 |
|----------------|-----------------|
| CrCl ≥30ml/min | give 100% dose  |
| CrCl <30ml/min | not recommended |

## REFERENCES

1. FOCUS (CR08) clinical protocol 2001
2. Calcium levofolinate SPC 06/2002 [www.medicines.org.uk](http://www.medicines.org.uk)
3. Bunn R & Ashley C, The Renal Drug Handbook Radcliffe Medical Press, Oxford;1999:61